Skip to main content


Why Are Physicians Silent About Outrageous Drug Prices?

MedPage Today

This article was written by Dr. Milton Packer, who wonders why physicians are struggling to get their priorities straight.

The Overpricing of Drugs (1.14.2022)

Dr. Jack Cush reviews the news and journal articles from the past week on This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.

Hold Myophenolate or Not with COVID-19 Vaccination?

While the American College of Rheumatology recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases patients (RMD) receiving COVID-19 vaccines, there is limited data on such an approach. A recent cohort study of RMD patients showed that holding MMF yielded higher antibody responses than continuing MMF.

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.

KEEPSaKe-1 Trial in Psoriatic Arthritis - IL-23 Inhibition is Effective

The results of the KEEPSaKE-1 study in psoriatic arthritis (PsA) has been published and shows that risankizumab (RIZ), an IL-23 inhibitor, showed significant clinical improvements when given to active PsA patients who failed or were intolerant to ≥1 csDMARD.

What Can JIA Patients Expect 18 Years In?

MedPage Today

Follow-up in a Scandinavian cohort of juvenile idiopathic arthritis (JIA) patients that began in 1997-2000 revealed a number of surprises, a new study indicated.

Biologic Treatment of Primary Sjogrens with Ianalumab

Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.

BEAT LUPUS - Belimumab after Rituximab in SLE

A recent trial published in Annals of Internal Medicine analyzed the effects of B-cell depletion (rituximab) followed by B-cell suppression (belimumab) and showed effective lowering of anti-dsDNA titers and and fewer severe flare in patients with systemic lupus erythematosus (SLE).

COVID-19 in Pregnant Rheumatic Women

The Global Rheumatology Alliance (GRA) has studied the outcomes of women with rheumatic disease who were pregnant at the time of infection with coronavirus disease 2019 (COVID-19).

2021 Rheumatology Year in Review

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Comorbidities Drive Risk of Severe Outcomes with COVID-19

The current edition of the MMWR from the CDC shows that among those vaccinated against COVID-19, there is a low risk of severe outcomes (hospitalization and death); the highest risk is seen in those with multiple comorbidities.

COVID Breakthrough Infections with Arthritis and HIV

MedPage Today

Among immunocompromised individuals vaccinated against COVID-19, solid organ transplant recipients as well as those with HIV and rheumatoid arthritis (RA) were significantly more likely to experience breakthrough infections versus people without immune dysfunction, a retrospective study found.